139 related articles for article (PubMed ID: 35728342)
21. Examination of a paradox: recurrent metastatic breast cancer incidence decline without improved distant disease survival: 1990-2011.
Malmgren J; Hurlbert M; Atwood M; Kaplan HG
Breast Cancer Res Treat; 2019 Apr; 174(2):505-514. PubMed ID: 30560462
[TBL] [Abstract][Full Text] [Related]
22. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
23. Genomic Characterization of De Novo Metastatic Breast Cancer.
Mullangi S; Vasan N
Clin Breast Cancer; 2022 Feb; 22(2):98-102. PubMed ID: 34949553
[TBL] [Abstract][Full Text] [Related]
24. Characteristics and follow-up of metastatic breast cancer in Ethiopia: A cohort study of 573 women.
Weiner CM; Mathewos A; Addissie A; Ayele W; Aynalem A; Wondemagegnehu T; Wienke A; Jemal A; Zerche P; Thomssen C; Seidler A; Kantelhardt EJ
Breast; 2018 Dec; 42():23-30. PubMed ID: 30149234
[TBL] [Abstract][Full Text] [Related]
25. Aggressive local therapy for
Liu B; Liu H; Liu M
Oncol Rep; 2023 Sep; 50(3):. PubMed ID: 37449542
[TBL] [Abstract][Full Text] [Related]
26. Differences in the Tumor Molecular and Microenvironmental Landscape between Early (Non-Metastatic) and De Novo Metastatic Primary Luminal Breast Tumors.
Lambrechts Y; Hatse S; Richard F; Boeckx B; Floris G; Desmedt C; Smeets A; Neven P; Lambrechts D; Wildiers H
Cancers (Basel); 2023 Aug; 15(17):. PubMed ID: 37686617
[No Abstract] [Full Text] [Related]
27. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
[No Abstract] [Full Text] [Related]
28. Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer.
Kanjanapan Y; Lok SW; Gibbs P; De Boer R; Yeo B; Greenberg S; Barnett F; Knott L; Richardson G; Wong R; Nottage M; Collins IM; Torres J; Lombard J; Johns J; Harold M; Malik L
Breast Cancer Res Treat; 2020 Nov; 184(1):87-95. PubMed ID: 32779037
[TBL] [Abstract][Full Text] [Related]
29.
Lord SJ; Bahlmann K; O'Connell DL; Kiely BE; Daniels B; Pearson SA; Beith J; Bulsara MK; Houssami N
EClinicalMedicine; 2022 Feb; 44():101282. PubMed ID: 35128368
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
31. Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed.
den Brok WD; Speers CH; Gondara L; Baxter E; Tyldesley SK; Lohrisch CA
Breast Cancer Res Treat; 2017 Feb; 161(3):549-556. PubMed ID: 28000014
[TBL] [Abstract][Full Text] [Related]
32. Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions.
Smith CEP; Marcom PK; Mitri Z; Ko NY
Breast Cancer Res Treat; 2022 Nov; 196(1):215-220. PubMed ID: 36087190
[TBL] [Abstract][Full Text] [Related]
33. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
34. Real-World Clinical Outcomes in Biological Subgroups of Breast Cancer in the Hospital District of Southwest Finland.
Teerenhovi H; Tuominen S; Nurmi-Rantala S; Hemmilä P; Ellonen A
Oncologist; 2021 Aug; 26(8):e1372-e1380. PubMed ID: 33955109
[TBL] [Abstract][Full Text] [Related]
35. The Difference in Prognostic Outcomes Between
Yamamura J; Kamigaki S; Fujita J; Osato H; Komoike Y
In Vivo; 2018; 32(2):353-358. PubMed ID: 29475920
[TBL] [Abstract][Full Text] [Related]
36.
Zhang L; Li Z; Zhang J; Wu Y; Zhu Y; Tong Z
Oncol Lett; 2020 Apr; 19(4):2884-2894. PubMed ID: 32218843
[TBL] [Abstract][Full Text] [Related]
37. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
Yamada A; Kumamaru H; Shimizu C; Taira N; Nakayama K; Miyashita M; Honma N; Miyata H; Endo I; Saji S; Sawaki M
Eur J Cancer; 2021 Sep; 154():157-166. PubMed ID: 34293663
[TBL] [Abstract][Full Text] [Related]
38. Immediate Breast Reconstruction in De Novo Metastatic Breast Cancer: An Analysis of 563 Cases Based on the SEER Database.
Chen H; Zhang M; Wang M; Zhang P; Bai F; Wu K
Clin Breast Cancer; 2019 Feb; 19(1):e135-e141. PubMed ID: 30497928
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2-Targeted Therapy.
Wong Y; Raghavendra AS; Hatzis C; Irizarry JP; Vega T; Horowitz N; Barcenas CH; Chavez-MacGregor M; Valero V; Tripathy D; Pusztai L; Murthy RK
Oncologist; 2019 Mar; 24(3):313-318. PubMed ID: 30139836
[TBL] [Abstract][Full Text] [Related]
40. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
